B. Riley Securities Reiterates Buy on Harrow, Raises Price Target to $29

B. Riley Securities analyst Sahil Kazmi reiterates Harrow with a Buy and raises the price target from $26 to $29.

Analyst UpgradesMay 15 09:11

Harrow Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/15/2024 69.59% B. Riley Securities $26 → $29 Reiterates Buy → Buy 04/11/2024 40.35% Craig-Hallum → $24

BenzingaMay 15 09:09

Harrow to Present at Two Investor Conferences in May

NASHVILLE, Tenn.--(BUSINESS WIRE)--$HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that management will participate in the following two investor

BusinesswireMay 15 06:00

Harrow Inc (HROW) Q1 2024 Earnings Call Transcript Highlights: Robust Growth and Strategic Advances

Yahoo FinanceMay 15 02:00

Earnings Call Summary | Harrow(HROW.US) Q1 2024 Earnings Conference

The following is a summary of the Harrow, Inc. (HROW) Q1 2024 Earnings Call Transcript:Financial Performance:Harrow Inc. reported a rise of 33% in revenues for Q1 2024 compared to Q1 2023.Increased it

Futu NewsMay 14 15:31 · Conference Call

Harrow Health's Promising Growth Trajectory and Strong Financial Outlook Reinforce Buy Rating

TipRanksMay 14 12:45